Commit to Cure Gala in Seattle, Washington
Honoring Dr. Philip Mease
Friday, May 31, 2019 at Hyatt Regency.
6:00 p.m. Cocktail Reception
7:00 p.m. Dinner, Entertainment, Program and Live Auction
May is Psoriatic Arthritis Action (PsA) Month. Culminating the National Psoriasis Foundation’s (NPF) annual campaign this year will be our national Commit to Cure Gala recognizing Dr. Philip Mease and his tireless efforts to support and help people living with psoriasis and psoriatic arthritis. NPF is proud to honor Dr. Mease, a leading international rheumatologist in psoriatic arthritis, with a Lifetime Achievement Award. As chair of NPF’s PsA Task Force, Dr. Mease helps guide our organization’s focus and initiatives as we work to address the disparities and challenges that people with PsA face.
Nearly one-third of the 8.3 million people currently living with psoriasis will develop psoriatic arthritis (PsA), and about half a million U.S. adults already have the disease. Without proper treatment, over half of those with PsA will have damage in five or more joints within 10 years, making PsA one of the most severely debilitating diseases in the world. The time between onset of symptoms and diagnosis is frequently two years or more. Unfortunately, a misdiagnosis or delay in diagnosis and treatment of even just six months can result in irreversible joint damage.
Lacking, however, is a single, accurate, replicable diagnostic instrument to identify PsA before joint damage occurs. PsA is one of the only arthritis’s still without this tool. In honor of Dr. Mease, all proceeds from the 2019 Commit to Cure Gala will go to NPF-funded PsA research including NPF’s recently launched PsA Diagnostic Test Grant to fund research to identify a PsA diagnostic test and bring that tool to clinical care to allow for the earliest possible identification and intervention for PsA.
We hope you will join us on May 31, 2019 for this spectacular evening of fine dining, entertainment and live auction!
About Dr. Philip Mease
Dr. Mease received his undergraduate and medical degrees from Stanford University. He completed residency in internal medicine and fellowship in rheumatology at the University of Washington. He cares for patients and directs the rheumatology research division at Swedish-Providence Health Systems and is Clinical Professor of Medicine at the University of Washington in Seattle.
Dr. Mease’s research interests have included psoriatic arthritis (PsA) and spondyloarthritis (SpA), rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia (FM) and osteoporosis. His work includes research on disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies for these conditions. His seminal 2000 Lancet paper established the efficacy of anti-TNF therapy in PsA. He has authored over 400 journal articles, numerous abstracts, and book chapters. He is a prolific international speaker at academic congresses, grand rounds and other educational activities for rheumatologists and dermatologists and is considered an international key opinion leader, researcher, mentor, educator and clinician regarding SpA and PsA. He is a reviewer for Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, Seminars in Arthritis and Rheumatism, New England Journal of Medicine, the Lancet, NPF’s Journal of Psoriasis & Psoriatic Arthritis and other journals.
Dr. Mease is past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), an international organization of over 800 rheumatology and dermatology researchers dedicated to research and education about psoriasis and PsA. He is a member of the Assessment of Spondyloarthritis International Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). He has served in an educational and advisory role for the FDA regarding PsA and SpA. Dr. Mease has been active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) research organization as a member of its steering committee and co-chair of the PsA and chronic pain working groups. He serves on the steering committee of the arthritis section of the International Consortium for Health Outcomes Measurement (ICHOM). He conducts disease state research in registries such as the Consortium of Rheumatology Researchers of North America (CORRONA) for which he is Director of the SpA and PsA registry arms. He is a member of The Rheumatology Education Group (TREG).
Dr Mease is a Master of the American College of Rheumatology (ACR) and has received its Medical Communicator of the Year Award. He teaches about PsA at ACR Meet the Professor sessions and is a prominent research and education presenter at ACR meetings. He is a co-chair of the ACR abstract review committee section on SpA and PsA. He served on the Voting Committee for the ACR-NPF PsA treatment guidelines task force. He is immediate-past President of the Northwest Rheumatism Society. Dr. Mease has served on the NPF Medical Advisory Board, currently co-chairs NPF’s PsA Task Force and has chaired and served as faculty for numerous NPF medical professional continuing medical education programs over the years focusing on collaborative care for psoriasis and psoriatic arthritis patients.